Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process ...

First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities ...

The enhanced yields will benefit the company’s immune globulin products, ASCENIV and BIVIGAM. Looking ahead, ADMA is committed to advancing its R&D platform and enhancing production capabilities ...

CAR NK-cell therapy prompted remission in 4 out of 9 patients, and a substantial response in a fifth The therapy can be made in advance with donor cells, while other CAR therapies must be handcrafted ...

Our immune systems weaken as we get older ... Inadequate ELOVL2 changes the balance of lipids in cells, impairing the development of B cells, the lymphocytes (white blood cells) responsible ...

The survivor is undergoing treatment at BHU’s Trauma Centre and has been diagnosed with Hepatitis-B, possibly contracted during her week-long captivity. Doctors suggest that her condition may have ...